Mofezolac

SKU: orb1220946

Description

Mofezolac (formerly known as Disopain or N-22) is a highly selective COX-1 (cyclooxygenase-1) inhibitor with COXs selectivity index > 6000.(In Vitro):Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay.Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib.(In Vivo):Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice.

Key Properties

• CAS Number: 78967-07-4
• MW: 339.35
• Purity: >98% (HPLC)
• Formula: C₁₉H₁₇NO₅
• SMILES: COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1
• Target: COX
• Solubility: DMSO:10 mM;Water:Insoluble;Ethanol:Insoluble

Bioactivity

• In Vivo:
  Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice. Animal model: Female ddY mice (4 week old, 18-27 g) injected with phenyl-p-benzoquinone (PQ). Dosage: 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg. Administration: Oral administration; once. Result: Dose-dependently suppressed the writhing induced by PQ injection in mice.
• In Vitro:
  Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay. Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

COX